All In Biotech

Drug Trial Radar · NCT01136551

Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A

An Open-label, Three-period, Crossover Study in Healthy Volunteers to Evaluate the Relative Bioavailability of Two Different Release Rate Controlled Release Formulations of Huperzine A (0.4mg)Compared to the Equivalent Dose of an Immediate Release Formulation.

Last checked: Nov 20, 2026Latest source record: Jun 3, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

8

Planned (sponsor's estimate)

Start

Sep 2010

Primary completion

Jan 2011

Study completion Apr 2011

Sponsor

Lead sponsor
Hadassah Medical OrganizationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hebrew University of Jerusalem
First posted
Jun 3, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to develop oral controlled release formulation of Huperzine A that will provide optimal pharmacokinetic profile of the drug enhancing safety and compliance, as possible cure to neurodegenerative disorders.

Conditions

  • Healthy
  • Bioavailability

Interventions

  • Huperzine ADrug

    Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic parameters of Huperzine A different formulationsTime frame: Blood samples will be taken for 36 hours after Huperzine A administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hadassah University Hospital

    Jerusalem, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.